Retrophin, Inc. (RTRX): Price and Financial Metrics
RTRX Price/Volume Stats
| Current price | $24.25 | 52-week high | $24.96 |
| Prev. close | $24.36 | 52-week low | $8.98 |
| Day low | $24.04 | Volume | 378,900 |
| Day high | $24.74 | Avg. volume | 412,277 |
| 50-day MA | $20.67 | Dividend yield | N/A |
| 200-day MA | $17.78 | Market Cap | 1.24B |
RTRX Stock Price Chart Interactive Chart >
Retrophin, Inc. (RTRX) Company Bio
Retrophin focuses on the development, acquisition, and commercialization of therapies for the treatment of serious, catastrophic, or rare diseases, including focal segmental glomerulosclerosis (FSGS), pantothenate kinase-associated neurodegeneration (PKAN), infantile spasms, nephrotic syndrome and others. The company was founded in 2011 and is based in San Diego, California.
Latest RTRX News From Around the Web
Below are the latest news stories about Retrophin Inc that investors may wish to consider to help them evaluate RTRX as an investment opportunity.
Retrophin enrolls patients for the study of sparsentan in IgA nephropathyRetrophin (RTRX) announced that the first 280 patients have been enrolled in the pivotal Phase 3 PROTECT Study evaluating the safety and efficacy of sparsentan in IgA nephropathy.Topline efficacy data from the 36-week proteinuria endpoint analysis are expected in Q3 2021. "As a result of achieving this important enrollment milestone... |
BofA bullish on Retrophin, sees 56% upsideBofA analyst Scott Puckhaber has initiated coverage on Retrophin ([[RTRX]] +3.9%) with a Buy rating and $30 (56% upside) price target.Topline data from two Phase 3 clinical trials evaluating lead candidate sparsentan are expected in H2 2021 in two kidney indications, ahead of previous guidance of H1 2022 mentioned in its Q2... |
Retrophin to Present at Upcoming Investor ConferencesSAN DIEGO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will participate in the following… |
Retrophin Reports Second Quarter 2020 Financial ResultsEnrollment ahead of schedule in Phase 3 PROTECT Study of sparsentan in IgAN; topline proteinuria data from both pivotal studies in FSGS and IgAN now… |
Retrophin (RTRX) Reports Q2 Loss, Misses Revenue EstimatesRetrophin (RTRX) delivered earnings and revenue surprises of 0.00% and -0.14%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock? |
RTRX Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | 32.66% |
| 5-year | -13.82% |
| YTD | N/A |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | 0.00% |
| 2019 | -37.25% |
| 2018 | 7.40% |
Continue Researching RTRX
Want to do more research on Retrophin Inc's stock and its price? Try the links below:Retrophin Inc (RTRX) Stock Price | Nasdaq
Retrophin Inc (RTRX) Stock Quote, History and News - Yahoo Finance
Retrophin Inc (RTRX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...